UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

British journal of cancer, 2002-07, Vol.87 (3), p.277-280

2002

Link zum Volltext

Verfügbarkeit prüfen

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Clinical pharmacology and therapeutics, 2007-07, Vol.82 (1), p.33-40

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of docetaxel

Clinical pharmacokinetics, 1999-02, Vol.36 (2), p.99-114

1999

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials

Clinical cancer research, 1997-08, Vol.3 (8), p.1261-1266

1997

Link zum Volltext

Verfügbarkeit prüfen

Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase

Biochemical pharmacology, 1996-10, Vol.52 (7), p.1103-1111

1996

Link zum Volltext

Verfügbarkeit prüfen

Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

Cancer chemotherapy and pharmacology, 1995, Vol.36 (2), p.176-179

1995

Link zum Volltext

Verfügbarkeit prüfen

Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients

Cancer research (Chicago, Ill.), 1996-08, Vol.56 (16), p.3689-3694

1996

Link zum Volltext

Verfügbarkeit prüfen

Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

European journal of clinical pharmacology, 2000-08, Vol.56 (5), p.395-398

2000

Link zum Volltext

Verfügbarkeit prüfen

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules

British journal of cancer, 2007-10, Vol.97 (8), p.1071-1076

2007

Link zum Volltext

Verfügbarkeit prüfen

Carbon Monoxide Disposition and Permeability-Surface Area Product in the Foetal Circulation of the Perfused Term Human Placenta

Placenta (Eastbourne), 2003-01, Vol.24 (1), p.8-11

2003

Link zum Volltext

Verfügbarkeit prüfen

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms

Naunyn-Schmiedeberg's archives of pharmacology, 1997-08, Vol.356 (2), p.257-262

1997

Link zum Volltext

Verfügbarkeit prüfen

Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes

Drug metabolism and disposition, 1998-08, Vol.26 (8), p.769

1998

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the Erythromycin Breath Test for Use in Cancer Patients

Clinical cancer research, 2000-09, Vol.6 (9), p.3480-3485

2000

Link zum Volltext

Verfügbarkeit prüfen

Frequency of cytochrome P 450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

European journal of clinical pharmacology, 2000-08, Vol.56 (5), p.395-398

2000

Link zum Volltext

Verfügbarkeit prüfen

Clinical and preclinical pharmacokinetics of raltitrexed

Clinical pharmacokinetics, 2000-12, Vol.39 (6), p.429-443

2000

Link zum Volltext

Verfügbarkeit prüfen

The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry

Journal of pharmaceutical and biomedical analysis, 1998-08, Vol.17 (4), p.785-792

1998

Link zum Volltext

Verfügbarkeit prüfen

More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

JNCI : Journal of the National Cancer Institute, 1999-01, Vol.91 (1), p.91-92

1999

Link zum Volltext

Verfügbarkeit prüfen

Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution Composition

Journal of pharmaceutical sciences, 1997-12, Vol.86 (12), p.1410-1416

1997

Link zum Volltext

Verfügbarkeit prüfen

The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)

Molecular pharmacology, 1999-12, Vol.56 (6), p.1346-1353

1999

Link zum Volltext

Verfügbarkeit prüfen

Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38

The Journal of pharmacology and experimental therapeutics, 1998-07, Vol.286 (1), p.578

1998

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of CPT-11: Impact on Activity

Annals of the New York Academy of Sciences, 2000-01, Vol.922 (1), p.205-215

RIVORY, LAURENT P.

2000

Link zum Volltext

Verfügbarkeit prüfen

The erythromycin breath test for the prediction of drug clearance

Clinical pharmacokinetics, 2001, Vol.40 (3), p.151-158

2001

Link zum Volltext

Verfügbarkeit prüfen

Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance

Cancer chemotherapy and pharmacology, 2000-01, Vol.45 (1), p.9-14

2000

Link zum Volltext

Verfügbarkeit prüfen

Molecular, cellular, and clinical aspects of the pharmacology of 20( S)camptothecin and its derivatives

Pharmacology & therapeutics (Oxford), 1995, Vol.68 (2), p.269-296

1995

Link zum Volltext

Verfügbarkeit prüfen

Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients

Cancer research (Chicago, Ill.), 1994-12, Vol.54 (24), p.6330-6333

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(98)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(72)
Life Sciences & Biomedicine
(70)
Humans
(57)
Biological And Medical Sciences
(50)
Medical Sciences
(47)
Pharmacology. Drug Treatments
(35)
Pharmacology & Pharmacy
(34)
Male
(30)
Animals
(27)
Camptothecin - Analogs & Derivatives
(27)
Female
(27)
Oncology
(24)
Antineoplastic Agents
(22)
Middle Aged
(22)
Adult
(19)
Aged
(17)
Camptothecin - Metabolism
(14)
Irinotecan
(13)
Chemotherapy
(12)
Liver - Metabolism
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

Clinical pharmacokinetics of docetaxel

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials

Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase

Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients

Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules

Carbon Monoxide Disposition and Permeability-Surface Area Product in the Foetal Circulation of the Perfused Term Human Placenta

The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms

Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes

Optimizing the Erythromycin Breath Test for Use in Cancer Patients

Frequency of cytochrome P 450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance

Clinical and preclinical pharmacokinetics of raltitrexed

The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry

More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin

Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution Composition

The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)

Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38

Metabolism of CPT-11: Impact on Activity

The erythromycin breath test for the prediction of drug clearance

Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance

Molecular, cellular, and clinical aspects of the pharmacology of 20( S)camptothecin and its derivatives

Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients

Suchergebnisse filtern